Acrivon adds immunology pillar, reports Q3 2026 results and ACR-2316 data ahead
Acrivon acquired a JAK1 inhibitor and a preclinical PKCθ program while reporting $77.8 million in cash expected to fund operations into the fourth quarter of 2027.
SEC filing